Titan Pharmaceuticals, Inc. Executive Chairman, Dr. Louis R. Bucalo, Retires to Pursue Other Interests
SOUTH SAN FRANCISCO, Calif.--(Business Wire)--
Titan Pharmaceuticals Inc. (AMEX:TTP), announced today that
Titan's Executive Chairman, Louis R. Bucalo, M.D., has left the
company and the board of directors to pursue other interests. Dr.
Bucalo founded Titan and was formerly President and CEO for many years
and its Chairman from 2000-2008.
E.M. Cavalier, a long-time member of the board of directors,
stated "Titan thanks Lou for his leadership and important
contributions to the company. As the key force behind our Spheramine
and Probuphine programs, as well as the acquisition of our other
current products in development, Dr. Bucalo substantially helped
create the foundation for Titan's future success, and the potential to
improve the lives of thousands of patients. We wish Lou well in his
future endeavors."
"I would like to thank the Board," stated Dr. Bucalo, "and all of
Titan's employees for their great efforts together in building Titan,
and toward improving lives from the development of new medical
treatments."
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (AMEX: TTP) is focused on the
late-stage development and commercialization of innovative treatments
for central nervous system disorders including schizophrenia, opioid
addiction, Parkinson's Disease and chronic pain. Titan has established
strategic partnerships with leading pharmaceutical companies,
including Vanda and Bayer Schering, to advance some of these programs.
For more information, please visit the Company's website at
www.titanpharm.com.
The press release may contain "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such statements include,
but are not limited to, any statements relating to the Company's
development program and any other statements that are not historical
facts. Such statements involve risks and uncertainties, including, but
not limited to, those risks and uncertainties relating to difficulties
or delays in development, testing, regulatory approval, production and
marketing of the Company's drug candidates, adverse side effects or
inadequate therapeutic efficacy of the Company's drug candidates that
could slow or prevent product development or commercialization, the
uncertainty of patent protection for the Company's intellectual
property or trade secrets, and the Company's ability to obtain
additional financing. Such statements are based on management's
current expectations, but actual results may differ materially due to
various factors, including those risks and uncertainties mentioned or
referred to in this press release.
Investors:
Titan Pharmaceuticals, Inc.
Robert Farrell, 650-244-4990
Executive Vice President & CFO
or
Media:
Pure Communications
Keri P. Mattox, 215-791-0105
Copyright Business Wire 2008
